Key Points
- United Therapeutics COO Michael Benkowitz conducted 11 separate sales of 22,500 shares each between Oct. 20 and Dec. 29, selling a total of 247,500 shares for approximately $115.7 million (most recent sale Dec. 29 at $502.79/share).
- For context, United Therapeutics has a market cap of about $21.4 billion, its stock was recently down 1.3%, and analysts have a consensus rating of "Moderate Buy" with an average target near $505 (several firms target $575–$587).
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of the company's stock in a transaction on Monday, December 29th. The shares were sold at an average price of $502.79, for a total transaction of $11,312,775.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Michael Benkowitz also recently made the following trade(s):
- On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $514.35, for a total transaction of $11,572,875.00.
- On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00.
- On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total value of $10,768,050.00.
- On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.91, for a total value of $10,797,975.00.
- On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $473.66, for a total value of $10,657,350.00.
- On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00.
- On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total value of $10,171,575.00.
- On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00.
- On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.50, for a total value of $9,393,750.00.
- On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total transaction of $9,616,725.00.
United Therapeutics Stock Down 1.3%
United Therapeutics stock opened at $496.19 on Wednesday. The company has a market capitalization of $21.37 billion, a PE ratio of 18.80, a PEG ratio of 4.99 and a beta of 0.86. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The firm's fifty day moving average is $474.25 and its 200 day moving average is $391.62.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the previous year, the firm posted $6.39 earnings per share. The business's revenue was up 6.8% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on UTHR shares. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a report on Monday. Jefferies Financial Group reaffirmed a "buy" rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Oppenheimer increased their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Royal Bank Of Canada boosted their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research note on Thursday, October 30th. Finally, Bank of America raised their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research note on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $505.00.
View Our Latest Stock Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 49 shares in the last quarter. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics in the 2nd quarter worth about $29,000. Abich Financial Wealth Management LLC bought a new position in United Therapeutics during the third quarter valued at about $44,000. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
